Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-year median follow-up of the phase III EV-302/KEYNOTE-A39 trial

Powles, T. B.; Heijden, M. S. Van der; Loriot, Y.; Bedke, J.; Valderrama, B. P.; Iyer, G.; Kikuchi, E.; Hoffman-Censits, J.; Vulsteke, C.; Drakaki, A.; Rausch, S.; Arafat, W.; Park, S. H.; Swami, U.; Li, J. -r.; Duran, I.; Gorla, S.; Moreno, B. Homet; Yu, X.; Lu, Y. -t.; Gupta, S.

dc.contributor.author	Rausch, Steffen
dc.date.accessioned	2026-06-12T07:58:25Z
dc.date.available	2026-06-12T07:58:25Z
dc.date.issued	2025
dc.identifier.issn	0923-7534
dc.identifier.uri	http://hdl.handle.net/10900/180739
dc.language.iso	en	de_DE
dc.publisher	Amsterdam : Elsevier	de_DE
dc.relation.uri	http://dx.doi.org/10.1016/j.annonc.2025.05.536	de_DE
dc.subject.ddc	610	de_DE
dc.title	Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-year median follow-up of the phase III EV-302/KEYNOTE-A39 trial	de_DE
dc.type	Article	de_DE
utue.quellen.id	20251118000000_00659
utue.publikation.seiten	1212-1219	de_DE
utue.personen.roh	Powles, T. B.
utue.personen.roh	Heijden, M. S. Van der
utue.personen.roh	Loriot, Y.
utue.personen.roh	Bedke, J.
utue.personen.roh	Valderrama, B. P.
utue.personen.roh	Iyer, G.
utue.personen.roh	Kikuchi, E.
utue.personen.roh	Hoffman-Censits, J.
utue.personen.roh	Vulsteke, C.
utue.personen.roh	Drakaki, A.
utue.personen.roh	Rausch, S.
utue.personen.roh	Arafat, W.
utue.personen.roh	Park, S. H.
utue.personen.roh	Swami, U.
utue.personen.roh	Li, J. -r.
utue.personen.roh	Duran, I.
utue.personen.roh	Gorla, S.
utue.personen.roh	Moreno, B. Homet
utue.personen.roh	Yu, X.
utue.personen.roh	Lu, Y. -t.
utue.personen.roh	Gupta, S.
dcterms.isPartOf.ZSTitelID	Annals of Oncology	de_DE
dcterms.isPartOf.ZS-Issue	10	de_DE
dcterms.isPartOf.ZS-Volume	36	de_DE
utue.fakultaet	04 Medizinische Fakultät	de_DE